Active Ingredient(s):Trametinib Dimethyl Sulfoxide FDA Approved: * May 29, 2013 Pharm Company: *GLAXOSMITHKLINE LLC Category:Cancer
Trametinib (trade name Mekinist & Meqsel both by Novartis ) is a cancer drug. It is a MEK inhibitor drug with anti-cancer activity.It inhibits MEK1 and MEK2.
Trametinib had good results for metastatic melanoma carrying the BRAF V600E mutation in a phase III clinical trial. In this mutation, the amino acid valine (V) at position 600 within the BRAF protein has become replaced by glutamic acid (E) making the mutant BRAF protein constitutively active.&a...
* May have multiple approval dates, manufacturers, or labelers.